Ulcerative colitis: Diagnosis and treatment

American Family Physician

Volumn 76, Issue 9, 2007, Pages 1323-1331

  Langan, Robert C ^a   Gotsch, Patricia B ^a   Krafczyk, Michael A ^a   Skillinge, David D ^a  

^a St Luke's Family Medicine Residency   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ENEMA; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE SODIUM SUCCINATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID;

ADRENAL INSUFFICIENCY; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; CANCER RISK; CANCER SCREENING; COLON CANCER; COLON RESECTION; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG COST; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; ENDOSCOPY; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; ILEITIS; INFECTION; INTESTINE OBSTRUCTION; IRRITABLE COLON; ISCHEMIC COLITIS; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; MALAISE; MYALGIA; NAUSEA; OSTEOPOROSIS; PROCTITIS; PSEUDOMEMBRANOUS COLITIS; QUALITY OF LIFE; SACCHAROMYCES CEREVISIAE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COLECTOMY; COLITIS, ULCERATIVE; COLONOSCOPY; DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL AGENTS; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 36248988026     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Carter MJ, Lobo AJ, Travis SP, for the IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;(53 suppl 5):V1-16.
2. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmstead County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336-43.
3. American Gastroenterological Association. Chronic intestinal disorders. Bethesda, Md.: American Gastroenterological Association, 2001. In: American Gastroenterology Association. The Burden of Gastrointestinal Diseases. Accessed June 13, 2007, at: http://www.gastro.org/user-assets/Documents/burden-report. pdf.
4. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117:514-21.
5. Boyko EJ, Koepsell TD, Perera DR, Inui TS. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med 1987;316:707-10.
6. Tanner AR, Raghunath AS. Colonic inflammation and nonsteroidal anti-inflammatory drug administration. An assessment of the frequency of the problem. Digestion 1988;41:116-20.
7. Kornbluth A, Sachar DB, for the Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85.
8. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12:4819-31.
9. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2(4947):1041-8.
10. Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am 2004;33:235-50, viii.
11. Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000;14:273-9.
12. Kefalides PT, Hanauer SB. Ulcerative colitis: diagnosis and management. Hospital Physician 2002:53-63. Accessed June 13, 2007, at: http://www.turner- white.com/pdf/hp_jun02_colitis.pdf.
13. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999;44:1-13.
14. Myers KA, Farquhar DR. The rational clinical examination. Does this patient have clubbing? JAMA 2001;286:341-7.
15. Roggeveen MJ, Tismenetsky M, Shapiro R. Best cases from the AFIP: ulcerative colitis. Radiographics 2006;26:947-51.
16. Fine KD, Seidel RH, Do K. The prevalence, anatomic distribution, and diagnosis of colonic causes of chronic diarrhea. Gastrointest Endosc 2000;51:318-26.
17. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease - 'colitis indeterminate'. J Clin Pathol 1978;31:567-77.
18. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006;101:2410-22.
19. Cima RR, Pemberton JH. Medical and surgical management of chronic ulcerative colitis. Arch Surg 2005;140:300-10.
20. Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol 1995;20:280-4.
21. Fitzgerald JM, Marsh TD. Mesalamine in ulcerative colitis. DICP 1991;25:140-5.
22. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478-85.
23. Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola C, Miglioli M, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998;41:93-7.
24. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-76.
25. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;(1):CD004277.
26. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis [Published correction appears in N Engl J Med 2006;354:2200]. N Engl J Med 2005;353:2462-76.
27. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995;20:117-22.
28. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001;44:1496-503.
29. Thirlby RC, Sobrino MA, Randall JB. The long-term benefit of surgery on health-related quality of life in patients with inflammatory bowel disease. Arch Surg 2001;136:521-7.
30. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567-74.
31. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
32. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
33. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
34. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, et al., for the ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, and ACS Endometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers [Published correction appears in CA Cancer J Clin 2001;51:150]. CA Cancer J Clin 2001;51:38-75.
35. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53.